CDKN2 (MTS1/p16^INK4A) Gene Alterations in Hematological Malignancies

References

• Fearon E. R. Oncogenes and tumor suppressor genes. Clinical Oncology, M. D. Abeloff, J. O. Armitage, A. S. Lichter, J. E. Niederhuber. Churchill Livingstone, New York 1995; 11–40
   Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., III, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–756
   PubMed Web of Science ®Google Scholar
• Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841–854
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9275: 1149–1163
   Web of Science ®Google Scholar
• Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704
   PubMed Web of Science ®Google Scholar
• Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massague J. Cloning of p27kp1 a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59
   PubMed Web of Science ®Google Scholar
• Lee M. H., Reynisdottir I., Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev. 1995; 9: 639–649
   PubMed Web of Science ®Google Scholar
• Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–707
   PubMed Web of Science ®Google Scholar
• Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257–261
   PubMed Web of Science ®Google Scholar
• Guan K. L., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Materw A. G., Xiong Y. Growth suppression by p18, a p16INK4A/MST1- and p14INK4 B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes & Dev. 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Hirai H., Roussel M. F., Kato J., Ashmun R. A., Sherr C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell Biol. 1995; 15: 2672–2681
   PubMed Web of Science ®Google Scholar
• Meyerson M., Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol. 1994; 14: 2077–2086
   PubMed Web of Science ®Google Scholar
• Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11: 1581–1588
   PubMed Web of Science ®Google Scholar
• Tam S. W., Shay J. W., Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res. 1994; 54: 5816–5820
   PubMed Web of Science ®Google Scholar
• Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993–1000
   PubMed Web of Science ®Google Scholar
• Stone S., Jiang P., Dayananth P., Tavtigen S. V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of p16 (MTS1) locus. Cancer Res. 1995; 55: 2988–2994
   PubMed Web of Science ®Google Scholar
• Mao L., Merlo A., Bedi G., Shapiro G. I., Edwards C. D., Rollins B. J., Sidransky D. A novel p16INK4A transcript. Cancer Res. 1995; 55: 2995–2997
   PubMed Web of Science ®Google Scholar
• Fueyo J., Gomez-Manzano C., Alfred Tung W. K., Clayman G. L., Liu T. J., Bruner J., Levin V. A., Kyritsis A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies transformed phenotype of glioma cells. Oncogene 1996; 12: 103–110
   PubMed Web of Science ®Google Scholar
• Jin X., Nguyen D., Zhang W. W., Kyritsis A. P., Roth J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 1995; 55: 3250–3253
   PubMed Web of Science ®Google Scholar
• Okamoto A., Hussain S. P., Hagiwara K., Spillare E. A., Rusin M. R., Demetrick D. J., Serrano M., Hannon G. J., Shiseki M., Zariwala M., Xiong Y., Beach D. H., Yokota J., Harris C. C. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995; 55: 1448–1451
   PubMed Web of Science ®Google Scholar
• Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W. G., Reiter A., Ludwig W. D., Zimmermann M., Schwaller J., Lee E., Miyoshi I., Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755–760
   PubMed Web of Science ®Google Scholar
• Nakamaki T., Kawamata N., Schwaller J., Tobler A., Fey M., Pakkala S., Lee Y. Y., Kim B. K., Fukuchi K., Tsuruoka N., Kahan J., Miller C. W., Koeffler H. P. Structural integrity of the cyclin-dependent kinase inhibitor genes. p15, p16, p18 in myeloid leukaemias. Br. J. Haematol. 1995; 91: 139–149
   PubMed Web of Science ®Google Scholar
• Shiohara M., El-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784
   PubMed Web of Science ®Google Scholar
• Ponce-Castañeda M. V., Lee M. H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J., Cordon-Cardo C. p27Kip1: Chromosomal mapping to 12p21-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995; 55: 1211–1214
   PubMed Web of Science ®Google Scholar
• Otterson G. A., Kratzke R. A., Coxon A., Kim Y. W., Kaye F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 3375–3378
   PubMed Web of Science ®Google Scholar
• Schmidt E. E., Ichimura K., Reifenberger G., Collins V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994; 54: 6321–6324
   PubMed Web of Science ®Google Scholar
• Lukas J., Aagaard L., Strauss M., Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 1995; 55: 4818–4823
   PubMed Web of Science ®Google Scholar
• Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A. T., Ally D. S., Sheahan M. D., Clerk W. H., Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nature Genet. 1994; 8: 15–21
   PubMed Web of Science ®Google Scholar
• Goldstein A. M., Fraser M. C., Struewing J. P., Hussussian C. J., Ranade K., Zametkin D. P., Fontaine L. S., Organic S. M., Dracopoli N. C., Clark W. H., Tucker M. A. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 1995; 333: 970–974
   PubMed Web of Science ®Google Scholar
• Caldas C., Hahn S. A., Costa L. T., Redston M. S., Schutte M., Seymour A. B., Weinstein C. L., Hruban R. H., Yeo C. J., Kern S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 1994; 8: 27–32
   PubMed Web of Science ®Google Scholar
• Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 1996; 12: 97–99
   PubMed Web of Science ®Google Scholar
• Reed J. A., Loganzo F. J., Shea C. R., Walker G. J., Flores J. F., Glendening J. M., Bogdany J. K., Shiel M. J., Haluska F. G., Fountain J. W., Albino A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2: tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995; 55: 2713–2718
   PubMed Web of Science ®Google Scholar
• Nishikawa R., Furnari F. B., Lin H., Arap W., Berger M. S., Cavenee W. K., Su Huang H. J. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995; 55: 1941–1945
   PubMed Web of Science ®Google Scholar
• Tenan M., Benedetti S., Finocchiaro G. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem. Biophys. Res. Commun. 1995; 217: 195–202
   PubMed Web of Science ®Google Scholar
• Glendening J. M., Flores J. F., Walker G. J., Stone S., Albino A. P., Fountain J. W. Homozygous loss of the p15INK4B gene (and not the p16INK4A gene) during tumor progression in sporadic melanoma patient. Cancer Res. 1995; 55: 5531–5535
   PubMed Web of Science ®Google Scholar
• Heyman M., Rasool O., Brandter L. B., Liu Y., Grandér D., Einhorn S. “Exclusive” p15INK4B gene deletion in acute lymphocytic leukemia include the E1β exon of the p16INK4A gene, (correspondence). Blood 1996; 87, 1657–1658
   Web of Science ®Google Scholar
• Weinberg R. A. Tumor suppressor gene. Science 1991; 254: 1138
   PubMed Web of Science ®Google Scholar
• Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219–222
   PubMed Web of Science ®Google Scholar
• Kundson A. G., Hethcote H. W., Brown B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. USA 1975; 72: 5116–5120
   PubMed Web of Science ®Google Scholar
• Ogawa S., Hangaishi A., Miyawaki S., Hirosawa S., Miura Y., Takeyama K., Kamada N., Ohtake S., Uike N., Shimazaki C., Toyama K., Hirano M., Mizoguchi H., Kobayashi Y., Furusawa S., Saito M., Emi N., Yazaki Y., Ueda R., Hirai H. Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86: 1548–1556
   PubMed Web of Science ®Google Scholar
• Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., Rutter J. L., Buckler A., Gabrielson E., Tockman M., Cho K. R., Hedrick L., Bova G. S., Isaacs W., Koch W., Schwab D., Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature genet. 1995; 11: 210–212
   PubMed Web of Science ®Google Scholar
• Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995; 1: 686–692
   PubMed Web of Science ®Google Scholar
• Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P. J., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common cancers. Cancer Res. 1995; 55: 4525–4530
   PubMed Web of Science ®Google Scholar
• Mori T., Miura K., Aoki T., Nishihara T., Mori S., Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (Multiple Tumor Suppressor/Cylin-dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994; 54: 3396–3397
   PubMed Web of Science ®Google Scholar
• Ranade K., Hussussian C. J., Sikorski R. S., Varmus H. E., Goldstein A. M., Tucker M. A., Serrano M., Hannon G. J., Beach D., Dracopoli N. C. Mutations associated with familial melanoma impair p16INK4 function. Nature genet. 1995; 10: 114–116
   PubMed Web of Science ®Google Scholar
• Chilcote R. R., Brown E., Rowley J. D. Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. N. Engl. J. Med. 1985; 313: 286
   PubMed Web of Science ®Google Scholar
• Okuda T., Shurtleff S. A., Valentine M. B., Raimondi S. C., Head D. R., Behm F., Curcio-Brint A. M., Liu Q., Pui C. H., Sherr C. J., Beach D., Look A. T., Downing J. R. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321–2330
   PubMed Web of Science ®Google Scholar
• Cayuela J. M., Madani A., Sanhes L., Stern M. H., Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180–2186
   PubMed Web of Science ®Google Scholar
• Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J. L., Bauters F., Wattel E., Fenaux P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657–663
   PubMed Web of Science ®Google Scholar
• Ohnishi H., Kawamura M., Ida K., Sheng X. M., Hanada R., Nobori T., Yamamori S., Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269–1275
   PubMed Web of Science ®Google Scholar
• Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F., Pelicci P. G., Lo Coco F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685–2690
   PubMed Web of Science ®Google Scholar
• Uchida T., Watanabe T., Kinoshita T., Murate T., Saito H., Hotta T. Mutational analysis of the CDKN2 (MTS1/p16INK4A) gene in primary B-cell lymphomas. Blood 1995; 86: 2724–2731
   PubMed Web of Science ®Google Scholar
• Stranks G., Height S. E., Mitchell P., Jadayel D., Yuille M. A. R., De Lord C., Clutterbuck R. D., Treleaven J. G., Powles R. L., Nacheva E., Oscier D. G., Karpas A., Lenoir G. M., Smith S. D., Millar J. L., Catovsky D., Dyer M. J. S. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995; 85: 893–901
   PubMed Web of Science ®Google Scholar
• Koduru P. R. K., Zariwala M., Soni M., Gong J. Z., Xiong Y., Broome J. D. Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 1995; 86: 2900–2905
   PubMed Web of Science ®Google Scholar
• Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412–2421
   PubMed Web of Science ®Google Scholar
• Lo K. W., Huang D. P., Lau K. M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 1995; 55: 2039–2043
   PubMed Web of Science ®Google Scholar
• Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotrophic virus type 1 infection. Blood 1995; 86: 3619–3639
   PubMed Web of Science ®Google Scholar
• Sanada I., Tanaka R., Kumagai E., Tsuda H., Nishimura H., Yamaguchi K., Kawano F., Fujiwara H., Takatsuki K. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985; 65: 649–654
   PubMed Web of Science ®Google Scholar
• Hatta Y., Hirama T., Miller C. W., Yamada Y., Tomonaga M., Koeffler H. P. Homozygous deletions of p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699–2704
   PubMed Web of Science ®Google Scholar
• Sill H., Goldman J. M., Cross N. C. P. Homozygous deletions of p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013–2016
   PubMed Web of Science ®Google Scholar
• Serra A., Gottardi E., Ragione F. D., Saglio G., Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 1995; 91: 625–629
   PubMed Web of Science ®Google Scholar
• Otsuki T., Clark H. M., Wellmann A., Jaffe E. S., Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995; 55: 1436–1440
   PubMed Web of Science ®Google Scholar
• Haider M. A., Cao X. B., Manshouri T., Chan L. L., Glassman A., Kantarjian H. M., Keating M. J., Beran M. S., Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 1995; 86: 311–315
   PubMed Web of Science ®Google Scholar
• Newcomb E. W., Rao I. S., Giknavorian S. S., Lee S. Y. Alterations of multiple tumor suppressor genes (p53(17p13), p16INK4A (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol. Carcinogen. 1995; 14: 141–146
   PubMed Web of Science ®Google Scholar
• Carins P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J. E., Sidransky D., Kamb A., Liu Q., Harshman K., Tavtigian S., Cordon-Cardo C., Skolnick M. H. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415–417
   PubMed Web of Science ®Google Scholar
• Hahn S. A., Schutte M., Hoque A. T. M. S., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–353
   PubMed Web of Science ®Google Scholar
• Puig S., Ruiz A., Lazaro C., Castel T., Lynch M., Palou J., Vilalta A., Weissenbach J., Mascaro M. J., Estivill X. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am. J. Hum. Genet., 57: 395–402
   PubMed Web of Science ®Google Scholar
• Spruck C. H., III, Gonzales-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumors. Nature 1994; 370: 183–184
   PubMed Web of Science ®Google Scholar
• Kyritsis A. P., Zhang B., Zhang W., Xiao M., Takeshima H., Bondy M. L., Cunningham J. E., Levin V. A., Bruner J. Mutations of p16 gene in gliomas. Oncogene 1996; 12: 63–67
   PubMed Web of Science ®Google Scholar
• Kratzke R. A., Otterson G. A., Lincoln C. E., Ewing S., Oie H., Geradts J., Kaye F. J. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst. 1995; 87: 1870–1875
   PubMed Web of Science ®Google Scholar